LogicBio Therapeutics, Inc.

( )
LOGC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 1.99%156.120.7%$1332.58m
PFEPfizer Inc. 0.50%34.370.9%$1246.54m
BMYBristol-Myers Squibb Co. 1.75%60.381.0%$850.51m
MRKMerck & Co., Inc. 1.34%73.140.7%$824.91m
ABBVAbbVie, Inc. 0.99%106.701.9%$789.53m
LLYEli Lilly & Co. 3.13%206.811.1%$757.17m
AZNAstraZeneca Plc 1.76%48.061.2%$496.61m
GSKGlaxoSmithKline Plc 1.84%34.910.2%$279.35m
SNYSanofi 1.50%46.590.2%$173.19m
NVSNovartis AG 0.64%84.030.2%$172.81m
VTRSViatris, Inc. 2.36%13.910.0%$134.20m
VERUVeru, Inc. 1.15%12.330.0%$101.62m
CVACCureVac NV 1.67%82.690.0%$94.10m
NVONovo Nordisk A/S 0.58%69.620.1%$88.53m
KALVKalVista Pharmaceuticals, Inc. -2.16%30.880.4%$79.85m

Company Profile

LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.